Medication info

Lozastar Plus Tablet

Prescription medicationTabletOralExpired
Ingredient · strength
Losartan Potassium›50mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Anguk Pharmaceutical Co., Ltd.
Appearance
Yellow oval film-coated tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Expired

MFDS item code 201901672 · Approved 2019.03.19

This product's status changed to Expired on 2024.03.19. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
○ Adults The usual dose of this medicine is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg daily are not recommended. The maximum blood pressure-lowering effect generally occurs about 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this medicine when the expected effect is not achieved with monotherapy. 1. Replacement therapy: Treatment with individually titrated doses of losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. The clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg should then be monitored continuously; if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose when creatinine clearance is 30 mL/min or higher. Use in patients with more severe renal impairment is not recommended, as loop diuretics are preferable to thiazide-type drugs in these patients. ○ Patients with hepatic impairment Use in patients with hepatic impairment requiring dose adjustment is not recommended, as the initial dose of losartan potassium for these patients, 25 mg, cannot be administered with this medicine.
Child dose
○ Children (under 18 years) There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children and adolescents.

Ingredients

Manufacturer
Anguk Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled with monotherapy

  • Hypertension
View approved original text

Used for patients with hypertension whose blood pressure is not sufficiently controlled by monotherapy.

How to take

Adult dose

○ Adults The usual dose of this medicine is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg daily are not recommended. The maximum blood pressure-lowering effect generally occurs about 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this medicine when the expected effect is not achieved with monotherapy. 1. Replacement therapy: Treatment with individually titrated doses of losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. The clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg should then be monitored continuously; if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose when creatinine clearance is 30 mL/min or higher. Use in patients with more severe renal impairment is not recommended, as loop diuretics are preferable to thiazide-type drugs in these patients. ○ Patients with hepatic impairment Use in patients with hepatic impairment requiring dose adjustment is not recommended, as the initial dose of losartan potassium for these patients, 25 mg, cannot be administered with this medicine.

Child dose

○ Children (under 18 years) There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children and adolescents.

Precautions

This medication can cause severe harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. It should not be used in patients with an allergy to this drug or its components, severe renal impairment, specific electrolyte disturbances, and some liver diseases or gout. Special caution is required when using this drug in patients with hypotension, kidney issues, liver disease, serum potassium abnormalities, certain vascular disorders, and diabetes. While taking this drug, various side effects such as dizziness, drowsiness, cough, skin rash, and muscle pain may occur; thus, any unusual symptoms should be discussed with a doctor. In particular, this drug can affect potassium levels, so potassium supplements should not be taken without consultation with a physician, and one should be cautious of possible dizziness when starting treatment due to its blood pressure-lowering effects. Furthermore, this drug may react sensitively to sunlight, potentially increasing the risk of skin cancer, so it’s important to reduce sun exposure and to periodically check the skin condition. This drug may interact with other medications, so it’s crucial to inform the doctor of any ongoing medications, and grapefruit juice should be avoided. Women who are pregnant or breastfeeding should avoid this medication, especially during breastfeeding as it may affect the baby, and should consult with a physician before making a decision. The safety of this drug in children and adolescents has not been established, thus it is not used in these populations. Regular blood tests to monitor kidney function and electrolyte status are necessary while taking this medication. Finally, this drug should be kept out of the reach of children and stored in its original container.

Side effects

  • Craniosynostosis
  • Anuria
  • Hypotension
  • Renal failure
  • Death
  • Abdominal pain
  • Edema
  • Palpitations
  • Low back pain
  • Dizziness
Show 128 more
  • Cough
  • Sinusitis
  • Upper respiratory infection
  • Rash
  • Angioedema
  • Skin peeling phenomenon
  • Hemolysis
  • Chest pain
  • Facial edema
  • Fever
  • Orthostatic hypotension
  • Syncope
  • Angina
  • Arrhythmia
  • Cerebrovascular accident
  • Myocardial infarction
  • Secondary atrioventricular block
  • Anorexia
  • Constipation
  • Toothache
  • Dry mouth
  • Indigestion
  • Flatulence
  • Gastritis
  • Vomiting
  • Fatigue
  • Anemia
  • Gout
  • Arm pain
  • Joint pain
  • Arthritis
  • Fibromyalgia
  • Hip pain
  • Joint swelling
  • Knee pain
  • Leg pain
  • Muscle cramps
  • Muscle weakness
  • Musculoskeletal pain
  • Myalgia
  • Shoulder pain
  • Muscle rigidity
  • Anxiety
  • Anxiety disorder
  • Ataxia
  • Confusion
  • Depression
  • Nightmares
  • Sensory loss
  • Insomnia
  • Decreased libido
  • Memory impairment
  • Migraine
  • Nervous hypersensitivity
  • Panic disorder
  • Sensory disturbance
  • Peripheral neuropathy
  • Sleep disorder
  • Drowsiness
  • Tremors
  • Shortness of breath
  • Nosebleed
  • Nasal congestion
  • Throat discomfort
  • Respiratory congestion
  • Rhinitis
  • Venous sinus disorder
  • Chest discomfort
  • Hair loss
  • Dermatitis
  • Dry skin
  • Purpura
  • Erythema
  • Flushing
  • Photosensitivity reaction
  • Pruritus
  • Sweating
  • Urticaria
  • Blurred vision
  • Ocular pain
  • Burning sensation
  • Conjunctivitis
  • Visual impairment
  • Taste disturbance
  • Tinnitus
  • Erectile dysfunction
  • Nocturia
  • Frequent urination
  • Urinary tract infection
  • Weakness
  • Pancreatitis
  • Jaundice
  • Sialadenitis
  • Cramps
  • Gastrointestinal irritation
  • Aplastic anemia
  • Agranulocytosis
  • Leukopenia
  • Thrombocytopenia
  • Purpura
  • Necrotizing vasculitis
  • Pneumonia
  • Pulmonary edema
  • Acute respiratory distress syndrome
  • Hyperglycemia
  • Diabetes
  • Muscle cramping
  • Agitation
  • Renal failure
  • Renal dysfunction
  • Interstitial nephritis
  • Skin and mucous membrane syndrome
  • Stevens-Johnson syndrome
  • Toxic epidermal necrolysis
  • Riel syndrome
  • Temporary blurred vision
  • Xanthopsia
  • Acute myopia
  • Acute angle-closure glaucoma
  • Dry cough
  • Thrombocytopenia
  • Vasculitis
  • Anaphylactic reaction
  • Hepatitis
  • Erythroderma
  • Hyperkalemia
  • Hyponatremia
  • Rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a container that restricts light. It is recommended to keep it at room temperature between 1 to 30 degrees Celsius. This will help maintain the effectiveness of the drug for a longer duration.

Appearance and packaging

Appearance

Yellow oval film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.